Global Rx-360 Consortium Aims To Curb Pharmaceutical Supply Chain Threats
This article was originally published in PharmAsia News
Executive Summary
Drug manufacturers are forming a consortium called Rx-360 to take the lead in protecting the global pharmaceutical supply chain from threats like the heparin adulterant potentially linked to deaths of 146 U.S. patients last year
You may also be interested in...
U.S. FDA, Industry Aim to Further Strengthen Pharma Supply Chain Quality
While the pharmaceutical industry and U.S. FDA have made progress in better controlling the pharmaceutical supply chain since the heparin crisis a few years ago, they recognize that more needs to be done, said FDA and industry officials at a recent PDA/FDA Pharmaceutical Supply Chain Workshop in Bethesda, Md
U.S. FDA, Industry Aim to Further Strengthen Pharma Supply Chain Quality
While the pharmaceutical industry and U.S. FDA have made progress in better controlling the pharmaceutical supply chain since the heparin crisis a few years ago, they recognize that more needs to be done, said FDA and industry officials at a recent PDA/FDA Pharmaceutical Supply Chain Workshop in Bethesda, Md
In Wake Of Heparin Deaths, FDA Set To Launch Pilot Project Aimed At Preventing Imports Of Adulterated Drugs
BEIJING - One year after adulterated heparin sourced from China began triggering scores of adverse reactions and deaths in U.S. patients, U.S. FDA is preparing to launch a voluntary pilot program aimed at helping prevent contaminated drugs from entering the country